Poster
Do you need to accelerate antibody discovery ?
In a single-day experiment, the Bruker Beacon® platform was employed to identify and isolate individual plasma cells secreting antibodies
against a tumor-associated antigen (TAA). The platform enabled high-throughput screening of antibodies with or without neutralizing activity,
and with or without cross-reactivity toward an antigen analog. This rapid, single-run workflow yielded a diverse panel of candidate antibodies.
These antibodies will undergo further characterization and be used in the development of therapeutic antibodies or antibody-drug conjugates to advance cancer treatment strategies
Download the poster
